SLC7A5 and acute myeloid leukemia: The anti-CD98 mAb (IGN523) used by these authors was developed by Hayes et al. (168) and has already been tested in a small phase 1 clinical trial with 19 R/R AML patients, which was completed in 2015 (NCT02040506, Table 5).